CytRx Corporation Share Price Nasdaq
Equities
US2328283013
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
04/06 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
15/05 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 644K 53.74M |
---|---|---|---|---|---|
Net income 2022 | -4M -334M | Net income 2023 | - 0 | EV / Sales 2022 | - |
Net cash position 2022 | 1.15M 95.63M | Net cash position 2023 | 2.04M 170M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.05
x | P/E ratio 2023 |
1.91
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.44% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Snowdy
CEO | Chief Executive Officer | 55 | 10/22/10 |
John Caloz
DFI | Director of Finance/CFO | 72 | 01/07/01 |
Cristina Newman
SEC | Corporate Secretary | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jennifer Simpson
CHM | Chairman | 55 | 29/21/29 |
Cary Claiborne
BRD | Director/Board Member | 64 | 27/22/27 |
Joel Caldwell
BRD | Director/Board Member | 69 | 12/17/12 |
1st Jan change | Capi. | |
---|---|---|
+46.49% | 56.61B | |
-7.63% | 39.62B | |
+35.76% | 39.25B | |
-6.90% | 28.28B | |
+11.15% | 26.44B | |
-16.39% | 20.12B | |
+29.48% | 12.51B | |
+30.40% | 12.48B | |
-0.82% | 12.2B |